Results 111 to 120 of about 75,066 (195)

Efficacy of glucagon-like peptide 1 analogues in psoriasis: A cohort study. [PDF]

JAAD Int
Bar D, Pavlotsky F, Baum S, Barzilai A.
europepmc   +1 more source

Levodopa Efficacy and GLP‐1 Receptor Agonists

Movement Disorders Clinical Practice, EarlyView.
Catherine Martinez, Christine Girges, Thomas Foltynie, Anne‐Marie Wills   +3 more
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli

Diabetes, Metabolic Syndrome and Obesity
Carol Cheney,1 Krystal Hunter,1 Marlena Klein2 1Cooper Medical School of Rowan University, Camden, NJ, USA; 2Internal Medicine Department, Cooper University Hospital, Camden, NJ, USACorrespondence: Carol Cheney, Cooper Medical School of Rowan University,
Cheney C, Hunter K, Klein M
doaj  

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective

Obesity, EarlyView.
ABSTRACT The off‐label use of glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses ...
Fernanda Baeza Scagliusi, Bruno Gualano, Pernille Andreassen, Cindi SturtzSreetharan, Sissel Due Jensen, Alexandra Brewis   +5 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation. [PDF]

J Am Chem Soc
Fallot LB, Anderson CA, Pinc JR, Stevenson A, Schleck MC, Hawryschuk E, Li OZ, Palchak JC, Toole JR, Kubiak Ii RW, Dear AJ, Michaels TCT, Limbocker R.   +12 more
europepmc   +1 more source

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo, Filipa Sofia Simas, Angela Ghiletchi, João Oliveira Torres, José Silva‐Nunes   +4 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes. [PDF]

Diabetes Ther
Panou T, Gouveri E, Popovic DS, Papazoglou D, Papanas N.   +4 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source